article · Journal of Medical Case Reports
BACKGROUND: Atorvastatin is widely prescribed for hyperlipidemia and is generally well tolerated. Auditory adverse effects are rarely reported, and statin-associated sensorineural hearing loss (SNHL) remains poorly characterized. CASE PRESENTATION: A 45-year-old Ethiopian woman developed bilateral tinnitus followed by progressive, symmetric bilateral SNHL 3 weeks after starting atorvastatin 40 mg daily. She had no other ototoxic risk factors. Pure-tone audiometry confirmed bilateral moderate SNHL. Given the temporal association and exclusion of alternatives, atorvastatin was discontinued. One week later, audiometry showed improvement to mild hearing loss, and at a 1-month follow-up, thresholds normalized with complete symptom resolution. She was subsequently switched to rosuvastatin 20 mg daily, with no recurrence at a 6-month follow-up. CONCLUSION: This case demonstrates that atorvastatin-associated SNHL can be reversible when recognized early. Prompt identification of new auditory symptoms and timely discontinuation of the offending medication may prevent permanent hearing impairment.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1186/s13256-026-06114-8
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
